Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Current Assets (2023 - 2025)

Historic Current Assets for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $184.9 million.

  • Contineum Therapeutics' Current Assets fell 1404.46% to $184.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $184.9 million, marking a year-over-year decrease of 1404.46%. This contributed to the annual value of $206.4 million for FY2024, which is 6161.18% up from last year.
  • Latest data reveals that Contineum Therapeutics reported Current Assets of $184.9 million as of Q3 2025, which was down 1404.46% from $176.8 million recorded in Q2 2025.
  • Over the past 5 years, Contineum Therapeutics' Current Assets peaked at $220.3 million during Q2 2024, and registered a low of $119.7 million during Q1 2024.
  • Over the past 3 years, Contineum Therapeutics' median Current Assets value was $188.5 million (recorded in 2025), while the average stood at $180.4 million.
  • Per our database at Business Quant, Contineum Therapeutics' Current Assets skyrocketed by 6161.18% in 2024 and then tumbled by 1973.54% in 2025.
  • Quarter analysis of 3 years shows Contineum Therapeutics' Current Assets stood at $127.7 million in 2023, then skyrocketed by 61.61% to $206.4 million in 2024, then fell by 10.4% to $184.9 million in 2025.
  • Its last three reported values are $184.9 million in Q3 2025, $176.8 million for Q2 2025, and $192.1 million during Q1 2025.